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by Elsevier B.V. This is an open accesAbstract Molybdenum cofactor deficiency (MCD) is a rare and ultimately fatal metabolic dis-
ease that results in extensive neurodegeneration in early infancy. The causal association of
MCD with sulfite oxidase deficiency, a known cause of subluxed lenses (ectopia lentis), has only
been recently defined. We report a 16-month-old Saudi Arabian male product of a consanguin-
eous union, who presented as a neonate with intractable seizures and a failure to thrive. Sub-
sequent examinations revealed hypotonia, laryngomalacia, global developmental delay,
progressive neurodegeneration and ectopia lentis. Urine analysis revealed elevated sulfocys-
tiene, xanthine and hypoxanthine, which suggested MCD. This diagnosis was confirmed by sub-
sequent genetic analysis, which disclosed a homozygous MOCS1 mutation. A significant family
history of sibling death, prior to diagnosis, from intractable seizures and respiratory distress at
three months of age, most likely represents the same affliction and suggests an underestima-
tion of MCD worldwide. This case underscores the need to consider and investigate MCD in all
cases of intractable infantile seizures. Thus, early diagnosis and confirmatory gene analysis
before permanent neurodegeneration is imperative for potential therapeutic intervention.
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Molybdenum cofactor deficiency (MCD) is a rare and fatal
metabolic disorder, which manifests in early childhood with
seizures refractory to medical intervention. First reported
in 1978 [1], the precise nature of the disease was only
recognized in 1980 [2]. Molybdenum cofactor is a crucial
component and is necessary for the synthesis of three en-
zymes: sulfite oxidase, xanthine dehydrogenase and alde-
hyde oxidase. However, only sulfite oxidase deficiency
(SOD) appears to be responsible for the serious neurode-
generative decline that ultimately leads to early mortality
[3]. Thus, SOD and MCD have similar clinical manifestations,
including ectopia lentis. It is possible but highly rare to
have isolated SOD without MCD.
Differentiation of MCD from isolated SOD is determined
using urinalysis. Both diseases have increased levels of
thiosulfate, but MCD also exhibits increased levels of
xanthine and hypoxanthine. In addition, plasma and urinary
uric acid levels are typically low or low-normal in MCD, while
it is normal in isolated SOD. Abnormal xanthine, hypoxan-
thine and uric acid levels result from xanthine dehydroge-
nase deficiency. Current hypotheses of the pathogenetic
mechanisms resulting in neurodegeneration are beyond the
scope of this paper, although it is sufficient to say that either
diminished levels of sulfates or toxic accumulation of sulfa-
containing metabolites are likely candidates [4].
MCD is an autosomal recessive disease. Thus, its preva-
lence is higher in isolated areas and where consanguinity is
common. Four genes are required for the production
pathway of molybdenum cofactor; MOCS1, MOCS2, MOCS3,
and GEPH. The most common mutation observed is in the
MOCS1 gene, followed by MOCS2 [4]. Less than 150 cases [5]
have been reported worldwide. Importantly, the incidence
is most likely an underestimation because many patients
with MCD die in early neonatal period without a diagnosis.
Due to the low incidence, a high index suspicion is required
prior to confirmatory tests. The diagnosis is made by the
clinical picture of intractable seizures that are mostly un-
responsive to anti-convulsant therapy, urinalysis and low
plasma and urinary uric acid. Neuro-radiology typically re-
veals non-specific changes similar to ischemic/hypoxic en-
cephalopathy. A finding of concurrent ectopia lentis
supports the clinical diagnosis of MCD. Prenatal diagnosis is
possible with an assay of sulfate oxidase activity and ge-
netic analysis of chorionic villus specimens [6,7].
Although effective treatment has not been established,
early diagnosis is important for providing information for
genetic counseling, screening of pregnant mothers sus-
pected of being heterozygous carriers and to help deter-
mine the real incidence of MCD. Furthermore, stable
molybdenum cofactor intermediates or dietary modifica-
tions, once identified, might help to ameliorate further
neurodegeneration or help to abate the seizures. Early
identification of ectopia lentis along with typical urinary
chemistry and neuroradiological changes is an important
complementary finding instrumental in making a timely
diagnosis of MCD. In this study, we describe a patient with a
complex combination of clinical signs, including intractable
seizures and ectopia lentis who was ultimately diagnosed
with molybdenum cofactor deficiency.Case report
A sixteen-month-old male, full-term product of a consan-
guineous union was referred to our clinic for ophthalmic
assessment. He was transferred from a local hospital in the
northern region of Saudi Arabia to King Faisal Specialist
Hospital at the age of 18 weeks for examination of neonatal
seizures, hypotonia, feeding difficulties and respiratory
distress. At birth, following an uneventful pregnancy and
delivery, he was noted to have meconium aspiration syn-
drome and developed intractable seizures. These were
successfully managed in the neonatal ICU with carbamaz-
epine and antibiotics. He was then readmitted soon after
discharge for poor sucking, hypotonia, and a failure to
thrive. He was diagnosed with infantile spasm-like seizures
and treated in the pediatric ICU with levetiracetam (Kep-
pra) and vigabatrin. Concomitant stridor and respiratory
distress was assessed and subsequently attributed to
laryngomalacia.
Importantly, the family history revealed a brother who
likewise developed intractable seizures, respiratory distress
and hypotonia in the neonatal period and died at three
months of age without a syndromic designation or initiation
of investigations. The parents are healthy second degree
cousins. The mother, a 25-year-old P2G2A0, had two brothers
and one sister who died in early infancy without diagnoses.
They were previously healthy. The father’s family is
completely healthy with no reported early deaths. Consan-
guinity is an acceptable practice in this family and region.
On examination, the patient had a dysmorphic face with
a broad nasal bridge, deep seated eyes, prominent cheeks,
micrognathia and large ears. Severe delay in developmental
milestones was also observed. There was no spontaneous
smile, no fixation or grasping of objects and no head con-
trol. Neurological examination revealed axial hypotonia
and peripheral spasticity with hyper-reflexia. The rest of
the systemic examination was normal and no organomegaly
was detected.
An EEG showed polyspikes with posterior dominance of
the left compared to the right. CSF analysis revealed
decreased glycine and uric acid, and non-ketotic hyper-
glycinemia was ruled out. Urinary xanthine, hypoxanthine,
and S-sulfocysteine levels were elevated. Tandem mass
spectrometry of the blood was negative for organic acids
and very long chain fatty acids, which simultaneously ruled
out several other inborn errors of metabolism. An MRI was
performed at five weeks of age, which revealed extensive
cortical atrophy, cystic degeneration of the white matter,
small brainstem and cerebellum, basal ganglion atrophy,
thin corpus callosum, and enlargement of the ventricles
and subarachnoid and peri-cerebellar CSF spaces (Fig. 1a
and b). A subsequent CT scan, at sixty weeks of age,
revealed further global encephalomalacia with a collapse
of the cystic white matter, enlarged ventricles and sub-
arachnoid spaces (Figs. 2 and 3a), and small, superiorly
subluxed lenses.
Ophthalmic examination, at sixteen months of age,
revealed no fixation or following in both eyes. The anterior
chambers were white and quiet with superiorly subluxed
lenses bilaterally (Figs. 3 and 4a,b). The dilated fundoscopy
was normal. Although the clinical manifestations, urinary
Figure 1 Five weeks of age e T1-weighted MRI of brain (a) sagittal view showing thin corpus callosum (blue arrow), small
brainstem (red arrow), cerebellum and enlarged ventricles and subarachnoid spaces; (b) axial views at the level of the thalamus,
demonstrating cystic changes in the bilateral basal ganglion (blue arrow), and cerebral white matter (red arrow) and dilated lateral
ventricles.
Figure 2 60 weeks of age e axial CT scan of the brain
revealing progressive neurodegeneration with severe global
encephalomalacia, collapse of cysts in the cerebral white
matter (yellow arrow), enlarged lateral ventricles and sub-
arachnoid spaces (red arrow).
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molybdenum cofactor deficiency, a blood specimen was
submitted for genetic analysis (Mayo Clinic, USA) and a
homozygous MOCS1 mutation was detected, which
confirmed the diagnosis of MCD. The parents have not been
investigated for heterozygosity and whether this case rep-
resents a new mutation cannot be determined at this time.
Multiple episodes of aspiration pneumonia from gastro-
esophageal reflux necessitated a Nissen fundoplication and
the placement of a feeding tube through which he receives
various fortified infant milk formulae. He is currently
oxygen-dependent and exhibits severe psychomotor retar-
dation. Phenobarbital was added to levetiracetam (Keppra)
and vigabatrin to control his seizures.
Discussion
Molybdenum cofactor deficiency is a severe progressive,
neurodegenerative, inborn error of metabolism, which ul-
timately results in death in early childhood. Early diagnosis
is essential but, due to its rarity and phenotypic variability,
it requires a high index of suspicion when a neonatologist is
presented with complex and wide-ranging clinical mani-
festations, which include intractable seizures. Indeed,
neonatal deaths may occur without syndromic designation
as might have occurred in our patient’s immediate family,
including a sibling who died of respiratory distress, hypo-
tonia and intractable seizures. His clinical picture and
course make MCD the mostly likely diagnosis. The maternal
siblings were described as “normal” prior to their untimely
demise and cannot be presumed to have had MCD.
Because the predominant clinical manifestations of MCD
are neurological and arise from SOD, the clinical course of
MCD and SOD are virtually identical. Ectopia lentis, a known
association of SOD is likewise observed in MCD and plays an
important role in establishing the diagnosis. Immediate
post-birth presentations have been reported [8e10] but
typically, clinical manifestations of MCD begin two weeksafter birth and early infancy [1,2,10]. In the initial de-
scriptions of MCD [1,2], the neonate had ectopia lentis at
the outset, while others have reported its development at a
later date. Although the patient had ectopia lentis at sixty
weeks, the small, malformed lens observed on the CT scan
in our patient indicates earlier subluxation (Fig. 3); thus its
precise onset is indeterminate.
Phenotypic variability is recognized and has been re-
ported in both MCD and SOD. In a cohort of ten patients,
Vijayakumar [10] recognized two forms of MCD: the more
common classical form presenting with neonatal rapidly
Figure 3 60 weeks of age e sagittal CT scan (a) revealing severe global volume loss, enlarged ventricles, subarachnoid space and
retro-cerebellar space (yellow arrows) and small, superiorly displaced lens e ectopia lentis (red arrow); (b) is a sagittal CT scan of a
normal baby, demonstrating normal brain development and normal shape, size and location of lens, for comparison.
38 M.A. Al-Obaidalla et al.progressive neurodegeneration and the mild atypical form
that presents later in life with a developmental delay.
Milder forms diagnosed after the incidental discovery of
ectopia lentis have been reported [10e12]. Our case rep-
resents the classical early-onset form.
Currently, there is neither an evidence-based treatment
regime for the management of MCD nor a means of delaying
progressive neurodegeneration. Molybdenum cofactor is
not sufficiently stable for systemic administration, but
there appears to be therapeutic potential in utilizing
biosynthetic intermediates or dietary modification. Anec-
dotal reports of successful treatments include the admin-
istration of cPMP (cyclic pyranopterin monophosphate),
an intermediate in molybdenum biosynthesis [13],
NMDA (N-methyl-D-aspartate) receptor inhibition withFigure 4 Bilateral ectopia lentis in a 16-month-old baby boy with
show superiorly subluxed lenses.dextromethorphan, thiamine and cysteine supplementation
and methionine-restricted diet [14]. Improvement of
biochemical profiles and neurological manifestations,
including a decline or complete cessation of seizures has
been reported. Thus, additional research is required before
a therapeutic regime can be established and universally
adopted. However, it is clear that the potential exists for
early intervention once individuals with this disorder are
identified. This makes early diagnosis of MCD, before per-
manent brain damage, imperative.
This report of a very rare and ultimately fatal metabolic
disease represents the need for a heightened index of
suspicion for MCD for all cases on intractable seizures.
Furthermore, this report underscores the similarities be-
tween MCD and isolated SOD. Both syndromes are likelymolybdenum cofactor deficiency (a) right eye and (b) left eye
Neonatal molybdenum cofactor deficiency 39under-diagnosed and under-reported particularly in iso-
lated areas and where consanguinity is common. The
addition of this confirmed case of molybdenum cofactor
deficiency to the current database, while adding to the
incidence and prevalence rates, will also help to establish
the phenotypic spectrum, detail the natural clinical course
and will enable an earlier recognition with implications for
future therapeutic intervention.
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